title: A phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study.
authors.affiliation: University of Oklahoma Health Science Center, Oklahoma City.
authors.forename: G B
authors.initials: GB
authors.lastname: Selby
authors.forename: C
authors.initials: C
authors.lastname: Upchurch
authors.forename: J
authors.initials: J
authors.lastname: Townsend
authors.forename: H J
authors.initials: HJ
authors.lastname: Eyre
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D001932:Brain Neoplasms / Q000188:drug therapy; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015206:Southwestern United States; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; C022121:fazarabine; D001374:Azacitidine